{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:26:40Z","timestamp":1792614400389,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.vaccine.2018.03.087","type":"journal-article","created":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T03:17:46Z","timestamp":1523071066000},"page":"2507-2509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab"],"prefix":"10.1016","volume":"36","author":[{"given":"Dominik","family":"Reher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Fuhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Nierhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2018.03.087_b0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/ejh.12520","article-title":"Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease","volume":"94","author":"Schubert","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.vaccine.2018.03.087_b0010","series-title":"Arzneiverordnungs-Report 2014: Aktuelle Daten, Kosten","author":"Schwabe","year":"2014"},{"issue":"9","key":"10.1016\/j.vaccine.2018.03.087_b0015","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2215\/CJN.06230614","article-title":"Molecules great and small: the complement system","volume":"10","author":"Mathern","year":"2015","journal-title":"Clin. J. Am Soc. Nephrol."},{"key":"10.1016\/j.vaccine.2018.03.087_b0020","unstructured":"Eculizumab-Soliris. Package insert. http:\/\/www.ema.europa.eu\/docs\/de_DE\/-document_library\/EPAR_-_Product_Information\/human\/000791\/WC500054208.pdf., (Accessed 5 April 2018)."},{"issue":"25","key":"10.1016\/j.vaccine.2018.03.087_b0025","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.vaccine.2018.03.087_b0030","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/CCM.0b013e31828a24a8","article-title":"Clinical features of critically ill patients with shiga toxin\u2013induced hemolytic uremic syndrome","volume":"41","author":"Braune","year":"2013","journal-title":"Crit. Care Med."},{"issue":"3","key":"10.1016\/j.vaccine.2018.03.087_b0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin. Microbiol. Rev."},{"issue":"7","key":"10.1016\/j.vaccine.2018.03.087_b0040","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00063-016-0209-1","article-title":"Bacterial meningitis in adults in emergency and rescue services","volume":"111","author":"Klein","year":"2016","journal-title":"Medizinische Klinik, Intensivmedizin und Notfallmedizin"},{"key":"10.1016\/j.vaccine.2018.03.087_b0045","first-page":"1","article-title":"Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study","author":"Friesecke","year":"2017","journal-title":"J Artif Organs"},{"issue":"12","key":"10.1016\/j.vaccine.2018.03.087_b0050","first-page":"2677","article-title":"Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock","volume":"35","author":"Kreymann","year":"2007","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.vaccine.2018.03.087_b0055","unstructured":"W. Hellenbrand, J. Koch, T. Harder, C. Bogdan, U. Heininger, T. Tenenbaum, M. Terhardt, U. Vogel, O. Wichmann, and R. von Kries. Background paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup b vaccine in persons at increased risk for meningococcal disease. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz, 58(11\u201312):1314\u20131343, 2015."},{"key":"10.1016\/j.vaccine.2018.03.087_b0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.03.087_b0065","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eimce.2017.02.003","article-title":"Meningococcemia in vaccinated patient under treatment with eculizumab","volume":"35","author":"Real","year":"2017","journal-title":"Enfermedades Infecciosas y Microbiologia clinica (English ed.)"},{"issue":"3","key":"10.1016\/j.vaccine.2018.03.087_b0070","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination","volume":"13","author":"Struijk","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.vaccine.2018.03.087_b0075","article-title":"Meningococcal disease in an international traveler on eculizumab therapy- United States, 2015","volume":"65","author":"Applegate","year":"2016","journal-title":"Morb. Mortal. Wkly Rep."},{"issue":"5","key":"10.1016\/j.vaccine.2018.03.087_b0080","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4cmenb) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet. Infect. Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2018.03.087_b0085","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18\u201324 months after immunization with one, two, or three doses of 4cmenb meningococcal serogroup b vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Human Vaccines Immunotherapeut."},{"key":"10.1016\/j.vaccine.2018.03.087_b0090","unstructured":"Committee for Medicinal Products for Human Use et al. European medicines agency: European public assessment report: Bexsero in. London: Technical report, available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002333\/WC500137881.pdf (Accessed 5 April 2018), 2013."},{"issue":"4","key":"10.1016\/j.vaccine.2018.03.087_b0095","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00277-017-2924-y","article-title":"Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (pnh) chronically treated with the terminal complement inhibitor eculizumab","volume":"96","author":"Alashkar","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.vaccine.2018.03.087_b0100","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"Morb. Mortal. Wkly Rep."},{"issue":"2","key":"10.1016\/j.vaccine.2018.03.087_b0105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3201\/eid2202.150369","article-title":"Effectiveness of meningococcal b vaccine against endemic hypervirulent Neisseria meningitidis w strain England","volume":"22","author":"Ladhani","year":"2016","journal-title":"Emerging Infectious Diseases"},{"issue":"7","key":"10.1016\/j.vaccine.2018.03.087_b0110","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup b vaccine (4cmenb) control Neisseria meningitidis capsular group x outbreaks in Africa?","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2018.03.087_b0115","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/infdis\/jix143","article-title":"Strains responsible for invasive meningococcal disease in patients with terminal complement pathway deficiencies","volume":"215","author":"Rosain","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.vaccine.2018.03.087_b0120","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1128\/IAI.01044-09","article-title":"Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies","volume":"78","author":"Hellerud","year":"2010","journal-title":"Infect. Immun."},{"issue":"7","key":"10.1016\/j.vaccine.2018.03.087_b0125","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab blocks vaccine-induced opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.03.087_b0130","unstructured":"R.B. Ellis-Pegler, C. Schwabe, I. Ajari, H. Robison, R. Sorensen, J. Lahey, W. Yang, M. Huang, J. Hui, H. Kocinsky, et al. An orally administered small molecule factor d inhibitor (ach-4471) for treatment of pnh and complement disease: preliminary phase 1 results in healthy volunteers. In Haematologica, volume 101(s1), 416, abstract n 2250, 2016."},{"issue":"2","key":"10.1016\/j.vaccine.2018.03.087_b0135","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1172\/JCI200112023","article-title":"A family with complement factor d deficiency","volume":"108","author":"Biesma","year":"2001","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.vaccine.2018.03.087_b0140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis","volume":"29","author":"Benamu","year":"2016","journal-title":"Current Opinion Infect. Diseases"},{"issue":"3","key":"10.1016\/j.vaccine.2018.03.087_b0145","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2452","article-title":"Meningococcal b vaccine failure with a penicillin-resistant strain in a young adult on long-term eculizumab","volume":"140","author":"Parikh","year":"2017","journal-title":"Pediatrics"},{"issue":"26","key":"10.1016\/j.vaccine.2018.03.087_b0150","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1182\/blood-2009-03-195966","article-title":"How I treat paroxysmal nocturnal hemoglobinuria","volume":"113","author":"Brodsky","year":"2009","journal-title":"Blood"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18304651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18304651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T12:57:00Z","timestamp":1534942620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18304651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":30,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0264410X18304651"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.087","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}